Thomas C. Pontani, Ph.D.
Partner
Partner
Areas of Expertise
Patent Litigation Including Litigation Under the Hatch-Waxman Act
U.S. International Trade Commission
Patent Infringement Investigations
Counseling on Patent Validity, Infringement, and Freedom to Operate
U.S. Patent Office Practice and Patent Prosecution
Counseling Clients on Hatch-Waxman Act Issues
Professional Summary
Dr. Pontani is a founding member of Cohen Pontani Lieberman & Pavane LLP. He began practicing as a patent agent in 1978 and practicing intellectual property law as an attorney in 1982. Dr. Pontani has extensive experience in prosecuting and litigating patents, with a specific focus on litigations under the Hatch-Waxman Act. Since enactment of the Hatch-Waxman Act in 1984 he has successfully represented U.S. and foreign clients under the Act, assisting them to enter the U.S. market, concerning generic drugs such as tamoxifen, ciprofloxacin, albuterol/ipratropium, terazozin, enalapril, norethindrone/ethinylestradiol, cyclosporin, bupropion, omeprazole, nabumeton, amoxicillin/clavulanic acid and others.
Dr. Pontani also has extensive experience in the preparation of opinions on patent validity, infringement, and freedom to operate issues in the chemical, pharmaceutical and mechanical arts.
In addition, Dr. Pontani has prosecuted patents especially in the chemical, pharmaceutical and mechanical arts for over 25 years. He has also counseled clients on intellectual property issues and has lectured on U.S. patent law and practice in Europe and in China.
Education
M.S., University of Innsbruck, 1974
Ph.D., Chemistry, University of Innsbruck, 1977
J.D., Fordham University, 1982
Admissions
New York
U.S. Patent and Trademark Office
U.S. District Courts, Southern, Eastern and Western Districts of New York; District of Columbia; Eastern and Western Districts of Wisconsin
U.S. Courts of Appeals for the District of Columbia and for the Federal Circuit
U.S. Court of Federal Claims
Memberships
New York State Bar Association
American Foreign Law Association
International Trade Commission Trial Lawyers Association
New York Patent, Trademark and Copyright Law Association
American Bar Association
Languages
German
Articles
“The Drug Price Competition and Patent Term Restoration Act - 10 Years Later,” Part I, Mitteilungen der deutschen Patentanwälte
“The Drug Price Competition and Patent Term Restoration Act - 10 Years Later,” Part II, Mitteilungen der deutschen Patentanwälte
“Das US-Gesetz ueber Arzneimittelpreiswettbewerb und Patent ...,” Teil I, Mitteilungen der deutschen Patentanwälte
“Das US-Gesetz ueber Arzneimittelpreiswettbewerb und Patent ...,” Teil II, Mitteilungen der deutschen Patentanwälte
Decisions
Novartis Pharm. Corp. v. Eon Labs Mfg., Inc., 363 F.3d 1306 (Fed. Cir. 2004).
Glaxo Wellcome Inc., v. Eon Labs Mfg., Inc., No. 00-Civ-9089, 2003 U.S. Dist LEXIS 14680, 2003 WL 22004874 (S.D.N.Y. Aug. 22, 2003).
Glaxo Wellcome Inc., v. Eon Labs Mfg., Inc., No. 00-Civ-9089, 2002 U.S. Dist. LEXIS 14950, 2002 WL 1874831 (S.D.N.Y. Aug. 13, 2002).
Valmet Paper Mach. Inc. v. Beloit Corp., 105 F.3d 1409 (Fed. Cir. 1997).
Bayer AG v. Barr Laboratories, Inc., No. 92-Civ-0381, 1996 U.S. Dist. LEXIS 13032, 1996 WL 509714 (S.D.N.Y. 1996).
Imperial Chem. Indus., PLC, v. Barr Labs., 795 F. Supp. 619 (S.D.N.Y. 1992).
Dr. Pontani is a founding member of Cohen Pontani Lieberman & Pavane LLP. He began practicing as a patent agent in 1978 and practicing intellectual property law as an attorney in 1982. Dr. Pontani has extensive experience in prosecuting and litigating patents, with a specific focus on litigations under the Hatch-Waxman Act. Since enactment of the Hatch-Waxman Act in 1984 he has successfully represented U.S. and foreign clients under the Act, assisting them to enter the U.S. market, concerning generic drugs such as tamoxifen, ciprofloxacin, albuterol/ipratropium, terazozin, enalapril, norethindrone/ethinylestradiol, cyclosporin, bupropion, omeprazole, nabumeton, amoxicillin/clavulanic acid and others.
Dr. Pontani also has extensive experience in the preparation of opinions on patent validity, infringement, and freedom to operate issues in the chemical, pharmaceutical and mechanical arts.
In addition, Dr. Pontani has prosecuted patents especially in the chemical, pharmaceutical and mechanical arts for over 25 years. He has also counseled clients on intellectual property issues and has lectured on U.S. patent law and practice in Europe and in China.
Education
M.S., University of Innsbruck, 1974
Ph.D., Chemistry, University of Innsbruck, 1977
J.D., Fordham University, 1982
Admissions
New York
U.S. Patent and Trademark Office
U.S. District Courts, Southern, Eastern and Western Districts of New York; District of Columbia; Eastern and Western Districts of Wisconsin
U.S. Courts of Appeals for the District of Columbia and for the Federal Circuit
U.S. Court of Federal Claims
Memberships
New York State Bar Association
American Foreign Law Association
International Trade Commission Trial Lawyers Association
New York Patent, Trademark and Copyright Law Association
American Bar Association
Languages
German
Articles
“The Drug Price Competition and Patent Term Restoration Act - 10 Years Later,” Part I, Mitteilungen der deutschen Patentanwälte
“The Drug Price Competition and Patent Term Restoration Act - 10 Years Later,” Part II, Mitteilungen der deutschen Patentanwälte
“Das US-Gesetz ueber Arzneimittelpreiswettbewerb und Patent ...,” Teil I, Mitteilungen der deutschen Patentanwälte
“Das US-Gesetz ueber Arzneimittelpreiswettbewerb und Patent ...,” Teil II, Mitteilungen der deutschen Patentanwälte
Decisions
Novartis Pharm. Corp. v. Eon Labs Mfg., Inc., 363 F.3d 1306 (Fed. Cir. 2004).
Glaxo Wellcome Inc., v. Eon Labs Mfg., Inc., No. 00-Civ-9089, 2003 U.S. Dist LEXIS 14680, 2003 WL 22004874 (S.D.N.Y. Aug. 22, 2003).
Glaxo Wellcome Inc., v. Eon Labs Mfg., Inc., No. 00-Civ-9089, 2002 U.S. Dist. LEXIS 14950, 2002 WL 1874831 (S.D.N.Y. Aug. 13, 2002).
Valmet Paper Mach. Inc. v. Beloit Corp., 105 F.3d 1409 (Fed. Cir. 1997).
Bayer AG v. Barr Laboratories, Inc., No. 92-Civ-0381, 1996 U.S. Dist. LEXIS 13032, 1996 WL 509714 (S.D.N.Y. 1996).
Imperial Chem. Indus., PLC, v. Barr Labs., 795 F. Supp. 619 (S.D.N.Y. 1992).
